Ephedra (Ephedra sinica)

Ephedra sinica contains ephedrine alkaloids that stimulate the sympathetic nervous system by activating adrenergic receptors. This herb has been banned in dietary supplements in the US due to serious cardiovascular risks including heart attack and stroke.

Origin & History

Ephedra sinica, commonly known as Chinese ephedra or ma huang, is a perennial shrub native to arid regions of China, Mongolia, and Central Asia, belonging to the Ephedraceae family. The herb consists of dried stems harvested in autumn and serves as the primary source for extracting alkaloids like ephedrine through various methods including ultra-high pressure extraction, supercritical CO₂, and acid-base fractionation.

Historical & Cultural Context

Ephedra sinica (ma huang) is referenced as a representative medicinal herb in traditional contexts, particularly as a source for ephedrine alkaloids. However, specific historical systems, traditional indications, or duration of use are not detailed in the extraction-focused research.

Health Benefits

• No clinical health benefits documented - research focuses only on extraction methods
• Traditional use as medicinal herb mentioned but specific benefits not detailed in available research
• Serves as source for ephedrine alkaloids but therapeutic applications not studied in provided literature
• No evidence quality available as no clinical trials found
• Safety profile and therapeutic effects remain undocumented in extraction-focused research

How It Works

Ephedra's primary alkaloids, ephedrine and pseudoephedrine, act as sympathomimetic agents by stimulating alpha and beta-adrenergic receptors. These compounds increase norepinephrine and dopamine release while inhibiting their reuptake, leading to increased heart rate, blood pressure, and thermogenesis. The alkaloids also stimulate the central nervous system by crossing the blood-brain barrier.

Scientific Research

The available research lacks any human clinical trials, RCTs, or meta-analyses on Ephedra sinica or its extracts. All provided studies focus exclusively on extraction methodology and chemical processing optimization without any clinical outcome data or PMIDs for therapeutic research.

Clinical Summary

Limited clinical research exists on Ephedra sinica specifically, with most studies focusing on purified ephedrine rather than the whole herb. Available research primarily examines extraction methods rather than therapeutic effects. The FDA banned ephedra-containing dietary supplements in 2004 following reports of adverse cardiovascular events. No current clinical trials support its safety or efficacy for any health condition.

Nutritional Profile

Ephedra sinica (Ma Huang) is not consumed as a nutritional food source; its profile centers on bioactive alkaloids and secondary metabolites rather than macronutrients. Primary bioactive compounds: total ephedrine alkaloids comprising 0.5–2.5% dry weight of stems, with individual constituents including L-ephedrine (the dominant alkaloid, typically 30–90% of total alkaloid fraction, approximately 0.5–2.0% dry weight), pseudoephedrine (0.1–0.5% dry weight), norephedrine, norpseudoephedrine, methylephedrine, and methylpseudoephedrine in smaller concentrations. Alkaloid concentration varies significantly by plant part: stems contain the highest alkaloid load; roots contain different alkaloids including ephedrannins (tannins) and few ephedrine-type alkaloids. Secondary phytochemicals include tannins (condensed and hydrolyzable, 5–10% dry weight), flavonoids including herbacetin, quercetin, and kaempferol glycosides (approximately 0.5–1.5% dry weight), proanthocyanidins, catechins, and volatile oils containing terpenes. Macronutrient content is negligible in medicinal dosing contexts: crude fiber present in stem material, trace proteins and carbohydrates in plant matrix, but these have no documented nutritional significance. Minerals detected include calcium, potassium, and magnesium at concentrations typical of dried plant material but not quantified as nutritional contributors. Bioavailability note: ephedrine alkaloids are rapidly and well-absorbed orally (bioavailability approximately 85–90%), with peak plasma concentrations reached within 1–2 hours; tannins may reduce alkaloid absorption slightly when co-present in whole-herb preparations compared to isolated alkaloids.

Preparation & Dosage

No clinically studied dosage ranges are available in the research, which focuses solely on extraction yields rather than therapeutic dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not documented in available research

Safety & Interactions

Ephedra carries significant cardiovascular risks including hypertension, arrhythmias, heart attack, and stroke, leading to its ban in dietary supplements. It can interact dangerously with MAO inhibitors, caffeine, and cardiovascular medications. Contraindicated in individuals with heart disease, hypertension, diabetes, thyroid disorders, and during pregnancy and breastfeeding. Side effects include anxiety, insomnia, tremors, headaches, and potentially fatal cardiac events.